Considering that leukemic blasts make up majority of blood cells in AML patients, we moved onto assessing the cellular source of type I IFN by testing IFNA1, IFNA2, and IFNB1 expression levels in isolated CD33+ leukemic blasts versus whole PBMCs (including CD33+ blasts). This evidence concerns the gene CD33 and acute myeloid leukemia.